



Pfizer New Zealand Limited
Level 1, Suite 1.4, Building B,
8 Nugent Street, Grafton, Auckland 1023
PO Box 3998, Shortland Street, Auckland, New Zealand 1140
Tel: 09 354 3065 Fax: 09 374 7630

Pfizer New Zealand Limited

30 September 2020

Dear Healthcare Professional,

NOTIFICATION OF TEMPORARY DISRUPTION TO PRODUCT SUPPLY

Pfizer New Zealand (Pfizer) wishes to advise that **NORIMIN™ 28 Day tablets** and **BREVINOR-1® 28 Day tablets** are currently out of stock.

Status	Presentation	Registration	Pharmacode®	Pack Size
OUT OF STOCK	NORIMIN™ 28 Day (0.5mg norethisterone / 0.035mg ethinylestradiol)	TT50-5909	410691	3 blisters x 28 tablets (84)
OUT OF STOCK	BREVINOR-1® 28 Day (1.0mg norethisterone / 0.035mg ethinylestradiol)	TT50-2610/4	303542	3 blisters x 28 tablets (84)

In addition, stock of the temporary **BREVINOR® 28 Day** (0.5mg norethisterone / 0.035mg ethinylestradiol) 4 blisters x 28 tablets (112) (Registration TT50-10759) introduced to maintain supply for patients during the initial shortage of **NORIMIN™ 28 Day** will shortly be exhausted.

Pfizer has experienced unforeseen long-term disruption to supply and, despite all efforts by Pfizer to mitigate the situation, we now anticipate being unable to re-supply these products until February 2021. Pfizer will advise should there be any change to this timeline.

To ensure continued access to appropriate contraceptive protection we encourage people taking these oral contraceptives who need more to discuss alternative contraceptive options with their prescriber.

Please refer to the **NORIMIN™ 28 Day and BREVINOR-1® 28 Day** Data Sheets and Consumer Medicines Information documents in www.medsafe.govt.nz for the complete product information.

We thank you in advance for your understanding and apologise for any inconvenience caused to you and your patients. For any medical or stock queries please contact Pfizer on 0800 736 363.

Please report any suspected adverse events via email to Pfizer Drug Safety at AUS.AEReporting@pfizer.com. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) in Dunedin online at <https://nzphvc.otago.ac.nz/reporting> or by email to nzphvc@otago.ac.nz

Yours faithfully,

Dr. Charanjeet Singh
Assoc. Medical Director, Internal Medicine
Pfizer New Zealand